Literature DB >> 30127923

Anti-Müllerian hormone inhibits proliferation and induces apoptosis in epithelial ovarian cancer cells by regulating the cell cycle and decreasing the secretion of stem cell factor.

Tiansong Zhang1, Linhao Deng2, Qian Xiong3, Shujun Su3, Jian Gu3.   

Abstract

Anti-Müllerian hormone (AMH) has been demonstrated to exhibit an inhibitory effect on the proliferation, invasion, metastasis and drug resistance of ovarian cancer. However, the mechanisms underlying these effects remain unclear. In the present study, 10 µg/ml recombinant human AMH (rhAMH) was administered to human OVCAR3 and OVCAR8 epithelial ovarian cancer (EOC) cell lines. Cell proliferation, apoptosis and cell cycle were analyzed. The level of stem cell factor (SCF) was detected using a reverse transcription-quantitative polymerase chain reaction and an ELISA, respectively. The exogenous addition of rhAMH significantly reduced the proliferation of OVCAR3 and OVCAR8 cell lines compared with the control group (P<0.01). The apoptosis rate in the rhAMH treated group (48 h) significantly increased compared with in the control group (OVCAR3, P=0.035; OVCAR8, P=0.020). The apoptosis rate increased at 72 h but did not exhibit a significant difference when compared with the 48 h group (OVCAR3, P=0.145; OVCAR8, P=0.296). The percentage of cells in the G1 phase in the rhAMH treated group (48 h) increased but was not significantly different compared with the control group (OVCAR3, P=0.070; OVCAR8, P=0.051). However, there was a significant difference at 72 h compared with the control group (OVCAR3, P=0.016; OVCAR8, P=0.019). At 48 h, the rhAMH-treated group exhibited a statistically significant inhibition of SCF mRNA expression levels (P=0.008), but no significant difference in the protein expression levels (P=0.101) compared with the control, though a significant inhibition was exhibited at 72 h (mRNA expression levels, P=0.005; protein expression levels, P=0.036). The present study revealed that rhAMH may be able to inhibit the proliferation and induce the apoptosis of EOC cells via G1/S-phase cell cycle arrest and the decreased secretion of SCF.

Entities:  

Keywords:  anti-Müllerian hormone; cell cycle; epithelial ovarian cancer; stem cell factor

Year:  2018        PMID: 30127923      PMCID: PMC6096103          DOI: 10.3892/ol.2018.8985

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  31 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  Expression and mutational analysis of tyrosine kinase receptors c-kit, PDGFRalpha, and PDGFRbeta in ovarian cancers.

Authors:  Sharon P Wilczynski; Yuan-Yuan Chen; Wengang Chen; Stephen B Howell; John E Shively; David S Alberts
Journal:  Hum Pathol       Date:  2005-03       Impact factor: 3.466

Review 3.  Mast cell: insight into remodeling a tumor microenvironment.

Authors:  Jing Liu; Yi Zhang; Jie Zhao; Zhuoshun Yang; Dapeng Li; Foad Katirai; Bo Huang
Journal:  Cancer Metastasis Rev       Date:  2011-06       Impact factor: 9.264

4.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

5.  Recombinant human Mullerian inhibiting substance inhibits long-term growth of MIS type II receptor-directed transgenic mouse ovarian cancers in vivo.

Authors:  Rafael Pieretti-Vanmarcke; Patricia K Donahoe; Paul Szotek; Thomas Manganaro; Mary K Lorenzen; James Lorenzen; Denise C Connolly; Elkan F Halpern; David T MacLaughlin
Journal:  Clin Cancer Res       Date:  2006-03-01       Impact factor: 12.531

6.  Mullerian Inhibiting Substance inhibits cervical cancer cell growth via a pathway involving p130 and p107.

Authors:  Thanh U Barbie; David A Barbie; David T MacLaughlin; Shyamala Maheswaran; Patricia K Donahoe
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-11       Impact factor: 11.205

7.  SCF-mediated mast cell infiltration and activation exacerbate the inflammation and immunosuppression in tumor microenvironment.

Authors:  Bo Huang; Zhang Lei; Gui-Mei Zhang; Dong Li; Chuanwang Song; Bo Li; Yanyan Liu; Ye Yuan; Jay Unkeless; Huabao Xiong; Zuo-Hua Feng
Journal:  Blood       Date:  2008-06-04       Impact factor: 22.113

Review 8.  Ovarian cancer stem cells: working towards the root of stemness.

Authors:  Rosemary Foster; Ronald J Buckanovich; Bo R Rueda
Journal:  Cancer Lett       Date:  2012-11-05       Impact factor: 8.679

Review 9.  Cancer stem cells: impact, heterogeneity, and uncertainty.

Authors:  Jeffrey A Magee; Elena Piskounova; Sean J Morrison
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

10.  Anti-Proliferative and Apoptotic Activities of Müllerian Inhibiting Substance Combined with Calcitriol in Ovarian Cancer Cell Lines.

Authors:  Yeon Soo Jung; Hee Jung Kim; Seok Kyo Seo; Young Sik Choi; Eun Ji Nam; Sunghoon Kim; Sang Wun Kim; Hyuck Dong Han; Jae Wook Kim; Young Tae Kim
Journal:  Yonsei Med J       Date:  2016-01       Impact factor: 2.759

View more
  4 in total

1.  Stage-specific modulation of antimüllerian hormone promotes primate follicular development and oocyte maturation in the matrix-free three-dimensional culture.

Authors:  Jing Xu; Maralee S Lawson; Shoukhrat M Mitalipov; Byung S Park; Fuhua Xu
Journal:  Fertil Steril       Date:  2018-11       Impact factor: 7.329

Review 2.  Bone Morphogenetic Protein Signaling in Cancer; Some Topics in the Recent 10 Years.

Authors:  Shogo Ehata; Kohei Miyazono
Journal:  Front Cell Dev Biol       Date:  2022-05-25

Review 3.  ACVR1 Function in Health and Disease.

Authors:  José Antonio Valer; Cristina Sánchez-de-Diego; Carolina Pimenta-Lopes; Jose Luis Rosa; Francesc Ventura
Journal:  Cells       Date:  2019-10-31       Impact factor: 6.600

4.  RNA expression differences in prostate tumors and tumor-adjacent stroma between Black and White Americans.

Authors:  Farah Rahmatpanah; Gabriela De Robles; Michael Lilly; Thomas Keane; Vinay Kumar; Dan Mercola; Pavneet Randhawa; Michael McClelland
Journal:  Oncotarget       Date:  2021-07-20
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.